drugset / Trial / NCT07548255
The Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined With Obinutuzumab in MCL
NaSingle-groupOpen-labelTreatment
Summary
A Single-Arm, Prospective Clinical Study Evaluating the Efficacy and Safety of Sonrotoclax, Zanubrutinib Combined with Obinutuzumab in the First-Line Treatment of Newly Diagnosed Intermediate-to-High-Risk Mantle Cell Lymphoma
Timeline
- Start
- 2026-04-20
- Primary completion
- 2029-03-01
- Completion
- 2029-03-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Obinutuzumab | Monoclonal antibody | 1000 mg | Intravenous |
| Subject | Sonrotoclax | Other / unclassified | 320 mg | — |
| Subject | Zanubrutinib | Small molecule | 160 mg | — |